Author:
Andrews Megan,Tousi Babak,Sabbagh Marwan N.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference26 articles.
1. Prince MJ. World Alzheimer Report 2016—improving healthcare for people living with dementia: coverage, quality and costs now and in the future. https://www.alz.co.uk/research/world-report-2016 . Accessed 9 Mar 2018.
2. Ramirez MJ. 5-HT6 receptors and Alzheimer’s disease (5-hydroxytryptamine 6) (report). Alzheimers Res Ther. 2013;5:15.
3. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014;76:27–50.
4. Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease. Expert Opin Drug Saf. 2004;3:425–40.
5. Nirogi R, Shinde A, Kambhampati RS, et al. Discovery and development of 1-(2-bromophenyl)sulfonyl-5-methoxy-3-(4-methyl-1-piperazinyl)methyl-1H-indole dimesylate monohydrate (SUVN-502): a novel, potent, selective and orally active serotonin 6 (5-HT) receptor antagonist for potential treatment of Alzheimer’s disease. J Med Chem. 2017;60:1843.
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献